Long‐Term Response to Intermittent Binimetinib in Patients with NRAS ‐Mutant Melanoma
出版年份 2020 全文链接
标题
Long‐Term
Response to Intermittent Binimetinib in Patients with
NRAS
‐Mutant Melanoma
作者
关键词
-
出版物
ONCOLOGIST
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-09-21
DOI
10.1634/theoncologist.2019-0656
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
- (2019) Hyejin Choi et al. Cell Reports
- LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
- (2019) A M Arance et al. ANNALS OF ONCOLOGY
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- MEK inhibitors for the treatment of NRAS mutant melanoma
- (2018) Saro Sarkisian et al. Drug Design Development and Therapy
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- MEK inhibition and immune responses in advanced melanoma
- (2017) Reinhard Dummer et al. OncoImmunology
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
- (2016) Marieke I.G. Raaijmakers et al. Oncotarget
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy
- (2015) Claudia Wellbrock et al. Pigment Cell & Melanoma Research
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
- (2013) M. D. Thakur et al. CANCER RESEARCH
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
- (2010) Marie C. Zipser et al. Pigment Cell & Melanoma Research
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search